The findings from this current study provide a molecular basis for a combinatory effect of high MD and BRCA1/2 gene mutations on breast cancer risk, through the repression of RASSF1A, a tumour suppressor gene known to be silenced by methylation in breast cancers. This evidence concerns the gene RASSF1 and breast carcinoma.